Literature DB >> 19279168

Evaluation of antibodies against different Epstein-Barr virus nuclear antigen 1 peptides in diagnosis of nasopharyngeal carcinoma.

Ai-Di Gu1, Hao-Yuan Mo, Jin-Xin Bei, Yan-Bo Xie, Li-Zhen Chen, Qi-Sheng Feng, Tiebang Kang, Yi-Xin Zeng.   

Abstract

Epstein-Barr virus nuclear antigen 1 (EBNA1) is a protein expressed consistently in nasopharyngeal carcinoma (NPC). Although antibody levels against three different EBNA1 peptides were all high in NPC patients, the correlation between any two biomarkers was low. Therefore, the selection of distinct EBNA1 peptides could render different results in serological detection for individuals with NPC.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19279168      PMCID： PMC2668280          DOI： 10.1128/CVI.00207-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  7 in total

Review 1.  EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus.

Authors:  E R Leight; B Sugden
Journal:  Rev Med Virol       Date:  2000 Mar-Apr       Impact factor: 6.989

2.  Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors.

Authors:  H M Cheng; Y T Foong; C K Sam; U Prasad; J Dillner
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

3.  The glycine-alanine repeating region is the major epitope of the Epstein-Barr nuclear antigen-1 (EBNA-1).

Authors:  H Rumpold; G H Rhodes; P L Bloch; D A Carson; J H Vaughan
Journal:  J Immunol       Date:  1987-01-15       Impact factor: 5.422

4.  Antibodies against Epstein-Barr virus gp78 antigen: a novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology.

Authors:  Ai-Di Gu; Yan-Bo Xie; Hao-Yuan Mo; Wei-Hua Jia; Miao-Yan Li; Ming Li; Li-Zhen Chen; Qi-Sheng Feng; Quentin Liu; Chao-Nan Qian; Yi-Xin Zeng
Journal:  J Gen Virol       Date:  2008-05       Impact factor: 3.891

5.  DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

Authors:  R Baer; A T Bankier; M D Biggin; P L Deininger; P J Farrell; T J Gibson; G Hatfull; G S Hudson; S C Satchwell; C Séguin
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

6.  Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.

Authors:  J Fachiroh; D K Paramita; B Hariwiyanto; A Harijadi; H L Dahlia; S R Indrasari; H Kusumo; Y S Zeng; T Schouten; S Mubarika; J M Middeldorp
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

7.  Novel hypotheses for the roles of EBNA-1 and BHRF1 in EBV-related cancers.

Authors:  D Horner; M Lewis; P J Farrell
Journal:  Intervirology       Date:  1995       Impact factor: 1.763
  7 in total
  2 in total

1.  Effects of silencing S100A8 and S100A9 with small interfering RNA on the migration of CNE1 nasopharyngeal carcinoma cells.

Authors:  Lin-Lin Yan; Yuan-Jiao Huang; Xiang Yi; Xue-Min Yan; Yan Cai; Qin He; Zi-Jian Han
Journal:  Oncol Lett       Date:  2015-03-31       Impact factor: 2.967

2.  Annexin A1 can inhibit the in vitro invasive ability of nasopharyngeal carcinoma cells possibly through Annexin A1/S100A9/Vimentin interaction.

Authors:  Ying Xiao; Chenjie Ouyang; Weiguo Huang; Yunlian Tang; Weiting Fu; Ailan Cheng
Journal:  PLoS One       Date:  2017-03-29       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.